The U.S. Food and Drug Administration (FDA) officially granted approval form Flusiva, an messenger ribonucleic acid (mRNA)-based influenza vaccine developed by Moderna. Indicated for seasonal influenza prevention in adults aged 50 years and older, mFlusiva marks the world’s first commercially approved flu vaccine built on mRNA technology. The landmark approval ends the decades-long dominance of traditional egg-based flu vaccines and launches a new technological chapter for global influenza prevention and control.
The FDA’s final decision follows a unanimous positive recommendation from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC). On June 18th, 2026, the committee voted 9-0 in support of approval, concluding that the clinical benefits of mFlusiva outweigh its potential risks and that its safety and efficacy profiles meet rigorous FDA licensing standards. This represents the VRBPAC’s first review and endorsement of a novel influenza vaccine since 2023, constituting a pivotal milestone in the global upgrade of flu vaccination technology.
mFlusiva delivers dual breakthroughs in manufacturing innovation and immunogenic performance compared with conventional influenza vaccines. For decades, traditional flu vaccines have relied on egg-based production, a cumbersome, time-consuming process vulnerable to annual viral drift and strain mismatch. Manufacturers must predict circulating flu strains months in advance, and inaccurate predictions frequently result in substantially reduced vaccine effectiveness.
Built on Moderna’s proven mRNA platform, mFlusiva eliminates the need for live virus cultivation and egg-dependent production. Instead, it utilizes synthetic mRNA molecules encoding key influenza antigen proteins, enabling drastically shortened production timelines, scalable manufacturing capacity, and rapid adaptation to evolving seasonal flu strains. This flexible production model solves the core pain points of slow iteration and poor strain compatibility inherent in traditional flu vaccines.
Key Phase 3 clinical trial data (NCT06602024) demonstrates superior protective performance. In seasonal influenza epidemic settings, mFlusiva achieved a relative vaccine efficacy of 26.6% against confirmed influenza illness compared with standard-dose conventional flu vaccines, with a 95.0% confidence interval of 16.7% to 35.4%. Designed to target three to four predominant influenza strains simultaneously, the vaccine elicits stronger, more durable, and broader-spectrum immune responses. It notably improves protection against severe illness and hospitalization, especially for high-risk elderly populations, effectively compensating for the weak cross-protection of traditional vaccines against variant strains.
Extensive clinical data verifies mFlusiva’s favorable and controllable safety profile. Adverse reactions are predominantly mild and transient, including local symptoms such as injection-site pain, redness and swelling, and systemic symptoms including low-grade fever and fatigue. No new serious safety risks were identified throughout clinical trials, and the overall adverse event rate is consistent with currently licensed seasonal flu vaccines, fully meeting adult vaccine safety specifications.
The approval of mFlusiva is a critical strategic milestone for Moderna to diversify its product portfolio and reduce reliance on Coronavirus Disease 2019 (COVID-19) vaccine revenue. Following the post-pandemic decline in coronavirus vaccine demand, Moderna has prioritized expanding its versatile mRNA technology platform into large-scale preventive vaccine markets. The multi-billion-dollar global seasonal influenza vaccine sector provides a vital commercial application scenario for the company’s technological transformation.
More importantly, the successful commercialization of an mRNA flu vaccine validates the universal adaptability and stability of mRNA technology, establishing a mature research and development paradigm for future vaccines against respiratory viral pathogens. Industry experts point out that traditional flu vaccine technology has long faced bottlenecks, with annual effectiveness typically hovering between 40.0% and 60.0% and significantly weakened protection in elderly populations.
As a next-generation immunization product, mFlusiva breaks through the technical limitations of conventional flu vaccines with its rapid strain iteration capability, high viral matching accuracy, and enhanced immune protection. It is expected to reshape the competitive landscape of the global influenza vaccine market. Furthermore, the approval accumulates valuable real-world clinical and commercial experience for expanding mRNA technology into broader fields of infectious disease prevention and chronic disease immunotherapy.
Moderna has announced accelerated commercial deployment plans for mFlusiva to support vaccination campaigns for the 2026 fall and winter flu season. Industry analysts predict that with ongoing technical optimization and expanded age indications, mFlusiva will eventually cover all age groups, becoming a core upgraded product for global routine influenza prevention. The launch will drive a fundamental shift in flu prevention strategies from passive strain matching to precise, proactive immune defense.